Introduction: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as
coadjuvants for the treatment of early motor symptoms in Parkinson's disease. They can …

Iron accumulation and tau protein deposition are pathological features of Alzheimer's (AD)
and Parkinson's diseases (PD). Soluble tau protein is lower in affected regions of these …

Mitochondrial dysfunction, iron accumulation, and oxidative damage are conditions often
found in damaged brain areas of Parkinson's disease. We propose that a causal link exists …

Background Treatment of paclitaxel (PTX)-induced peripheral neuropathy (PIPN) is full of
challenges because of the unclear pathogenesis of PIPN. Herbal folk medicine Khellin (Khe) …

Abstract Parkinson's disease (PD), a neurodegenerative disorder, is traditionally classified
as a movement disorder. Patients typically suffer from many motor dysfunctions. Presently …

While iron is a nutrient metal, iron overload can result in multiple organ failures. Iron
chelators, such as deferoxamine, are commonly used to ameliorate iron overload conditions …

Neuronal lesions in Parkinson's disease (PD) are commonly associated with α-synuclein (α-
Syn)-induced cell damage that are present both in the central and peripheral nervous …

Monoamine oxidases (MAOs) are involved in the oxidative deamination of different amines
and neurotransmitters. This pointed them as potential targets for several disorders and along …

Understandings of the disturbed iron metabolism in Parkinson's disease (PD) are largely
from the perspectives of neurons. Neurodegenerative processes in PD trigger universal and …

Abstract A series of (3-hydroxypyridin-4-one)-coumarin hybrids were developed and
investigated as potential multitargeting candidates for the treatment of Alzheimer's disease …